Evogene (EVGN) Depreciation and Depletion (2016 - 2025)
Evogene (EVGN) posted Depreciation and Depletion of $263000.0 for Q4 2025, down 6.41% sequentially from $281000.0 in Q3 2025, and down 40.36% YoY from $441000.0 in Q4 2024.
Evogene (EVGN) Depreciation and Depletion (2016 - 2025) Analysis & Trends
Evogene has reported Depreciation and Depletion for 10 years, with the latest figure at $263000.0 in Q4 2025.
- Quarterly Depreciation and Depletion fell 40.36% year-over-year to $263000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.2 million (down 17.66% YoY) and the FY2025 annual result came in at $1.1 million, down 17.16% from the prior year.
- Depreciation and Depletion eased to $263000.0 in Q4 2025 per EVGN's latest filing, from $281000.0 in the prior quarter.
- Over five years, Depreciation and Depletion peaked at $441000.0 in Q4 2024 and troughed at $209000.0 in Q3 2024.
- A 5-year average of $358333.3 and a median of $372500.0 in 2022 frame the typical range for Depreciation and Depletion.
- The sharpest annual moves came in 2024 and 2025: Depreciation and Depletion slumped 49.76% in 2024, then soared 34.45% in 2025.
- Over 5 years, Depreciation and Depletion stood at $317000.0 in 2021, then grew by 24.92% to $396000.0 in 2022, then rose by 5.56% to $418000.0 in 2023, then gained by 5.5% to $441000.0 in 2024, then plunged by 40.36% to $263000.0 in 2025.
- According to Business Quant data, Depreciation and Depletion over the past three periods registered $263000.0, $281000.0, and $441000.0 for Q4 2025, Q3 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 263,000.00 |
| Dec 31, 2025 | 263,000.00 |
| Sep 30, 2025 | 281,000.00 |
| Sep 30, 2025 | 281,000.00 |
| Dec 31, 2024 | 441,000.00 |
| Dec 31, 2024 | 441,000.00 |
| Sep 30, 2024 | 209,000.00 |
| Sep 30, 2024 | 209,000.00 |
| Jun 30, 2024 | 374,000.00 |
| Jun 30, 2024 | 374,000.00 |
| Mar 31, 2024 | 426,000.00 |
| Mar 31, 2024 | 426,000.00 |
| Dec 31, 2023 | 418,000.00 |
| Dec 31, 2023 | 418,000.00 |
| Sep 30, 2023 | 416,000.00 |
| Sep 30, 2023 | 416,000.00 |
| Jun 30, 2023 | 406,000.00 |
| Jun 30, 2023 | 406,000.00 |
| Mar 31, 2023 | 401,000.00 |
| Mar 31, 2023 | 401,000.00 |